Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface

I.J. Vries - van Leeuwen, de, D. Da Costa Pereira, K.D. Flach, S.R. Piersma, C. Haase, D. Bier, Z. Yalcin, R. Michalides, K.A.. Feenstra, C.R. Jiménez, T.F.A. Greef, de, L. Brunsveld, C. Ottmann, W. Zwart, A.H. Boer, de

Research output: Contribution to journalArticleAcademicpeer-review

53 Citations (Scopus)
3 Downloads (Pure)

Abstract

Estrogen receptor alpha (ERa) is involved in numerous physiological and pathological processes, including breast cancer. Breast cancer therapy is therefore currently directed at inhibiting the transcriptional potency of ERa, either by blocking estrogen production through aromatase inhibitors or antiestrogens that compete for hormone binding. Due to resistance, new treatment modalities are needed and as ERa dimerization is essential for its activity, interference with receptor dimerization offers a new opportunity to exploit in drug design. Here we describe a unique mechanism of how ERa dimerization is negatively controlled by interaction with 14-3-3 proteins at the extreme C terminus of the receptor. Moreover, the small-molecule fusicoccin (FC) stabilizes this ERa/14-3-3 interaction. Cocrystallization of the trimeric ERa/14-3-3/FC complex provides the structural basis for this stabilization and shows the importance of phosphorylation of the penultimate Threonine (ERa-T594) for high-affinity interaction. We confirm that T594 is a distinct ERa phosphorylation site in the breast cancer cell line MCF-7 using a phospho-T594–specific antibody and by mass spectrometry. In line with its ERa/14-3-3 interaction stabilizing effect, fusicoccin reduces the estradiol-stimulated ERa dimerization, inhibits ERa/chromatin interactions and downstream gene expression, resulting in decreased cell proliferation. Herewith, a unique functional phosphosite and an alternative regulation mechanism of ERa are provided, together with a small molecule that selectively targets this ERa/14-3-3 interface.
Original languageEnglish
Pages (from-to)8894-8899
JournalProceedings of the National Academy of Sciences of the United States of America (PNAS)
Volume110
Issue number22
DOIs
Publication statusPublished - 2013

Fingerprint

14-3-3 Proteins
Estrogen Receptor alpha
Pharmaceutical Preparations
Dimerization
Breast Neoplasms
Phosphorylation
Physiological Phenomena
Aromatase Inhibitors
Estrogen Receptor Modulators
Drug Design
Pathologic Processes
Threonine
Chromatin

Cite this

Vries - van Leeuwen, de, I. J., Da Costa Pereira, D., Flach, K. D., Piersma, S. R., Haase, C., Bier, D., ... Boer, de, A. H. (2013). Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 110(22), 8894-8899. https://doi.org/10.1073/pnas.1220809110
Vries - van Leeuwen, de, I.J. ; Da Costa Pereira, D. ; Flach, K.D. ; Piersma, S.R. ; Haase, C. ; Bier, D. ; Yalcin, Z. ; Michalides, R. ; Feenstra, K.A.. ; Jiménez, C.R. ; Greef, de, T.F.A. ; Brunsveld, L. ; Ottmann, C. ; Zwart, W. ; Boer, de, A.H. / Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface. In: Proceedings of the National Academy of Sciences of the United States of America (PNAS). 2013 ; Vol. 110, No. 22. pp. 8894-8899.
@article{4dc7faaf4a944a93995fa63c23cda5f0,
title = "Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface",
abstract = "Estrogen receptor alpha (ERa) is involved in numerous physiological and pathological processes, including breast cancer. Breast cancer therapy is therefore currently directed at inhibiting the transcriptional potency of ERa, either by blocking estrogen production through aromatase inhibitors or antiestrogens that compete for hormone binding. Due to resistance, new treatment modalities are needed and as ERa dimerization is essential for its activity, interference with receptor dimerization offers a new opportunity to exploit in drug design. Here we describe a unique mechanism of how ERa dimerization is negatively controlled by interaction with 14-3-3 proteins at the extreme C terminus of the receptor. Moreover, the small-molecule fusicoccin (FC) stabilizes this ERa/14-3-3 interaction. Cocrystallization of the trimeric ERa/14-3-3/FC complex provides the structural basis for this stabilization and shows the importance of phosphorylation of the penultimate Threonine (ERa-T594) for high-affinity interaction. We confirm that T594 is a distinct ERa phosphorylation site in the breast cancer cell line MCF-7 using a phospho-T594–specific antibody and by mass spectrometry. In line with its ERa/14-3-3 interaction stabilizing effect, fusicoccin reduces the estradiol-stimulated ERa dimerization, inhibits ERa/chromatin interactions and downstream gene expression, resulting in decreased cell proliferation. Herewith, a unique functional phosphosite and an alternative regulation mechanism of ERa are provided, together with a small molecule that selectively targets this ERa/14-3-3 interface.",
author = "{Vries - van Leeuwen, de}, I.J. and {Da Costa Pereira}, D. and K.D. Flach and S.R. Piersma and C. Haase and D. Bier and Z. Yalcin and R. Michalides and K.A.. Feenstra and C.R. Jim{\'e}nez and {Greef, de}, T.F.A. and L. Brunsveld and C. Ottmann and W. Zwart and {Boer, de}, A.H.",
year = "2013",
doi = "10.1073/pnas.1220809110",
language = "English",
volume = "110",
pages = "8894--8899",
journal = "Proceedings of the National Academy of Sciences of the United States of America (PNAS)",
issn = "0027-8424",
number = "22",

}

Vries - van Leeuwen, de, IJ, Da Costa Pereira, D, Flach, KD, Piersma, SR, Haase, C, Bier, D, Yalcin, Z, Michalides, R, Feenstra, KA, Jiménez, CR, Greef, de, TFA, Brunsveld, L, Ottmann, C, Zwart, W & Boer, de, AH 2013, 'Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface', Proceedings of the National Academy of Sciences of the United States of America (PNAS), vol. 110, no. 22, pp. 8894-8899. https://doi.org/10.1073/pnas.1220809110

Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface. / Vries - van Leeuwen, de, I.J.; Da Costa Pereira, D.; Flach, K.D.; Piersma, S.R.; Haase, C.; Bier, D.; Yalcin, Z.; Michalides, R.; Feenstra, K.A..; Jiménez, C.R.; Greef, de, T.F.A.; Brunsveld, L.; Ottmann, C.; Zwart, W.; Boer, de, A.H.

In: Proceedings of the National Academy of Sciences of the United States of America (PNAS), Vol. 110, No. 22, 2013, p. 8894-8899.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface

AU - Vries - van Leeuwen, de, I.J.

AU - Da Costa Pereira, D.

AU - Flach, K.D.

AU - Piersma, S.R.

AU - Haase, C.

AU - Bier, D.

AU - Yalcin, Z.

AU - Michalides, R.

AU - Feenstra, K.A..

AU - Jiménez, C.R.

AU - Greef, de, T.F.A.

AU - Brunsveld, L.

AU - Ottmann, C.

AU - Zwart, W.

AU - Boer, de, A.H.

PY - 2013

Y1 - 2013

N2 - Estrogen receptor alpha (ERa) is involved in numerous physiological and pathological processes, including breast cancer. Breast cancer therapy is therefore currently directed at inhibiting the transcriptional potency of ERa, either by blocking estrogen production through aromatase inhibitors or antiestrogens that compete for hormone binding. Due to resistance, new treatment modalities are needed and as ERa dimerization is essential for its activity, interference with receptor dimerization offers a new opportunity to exploit in drug design. Here we describe a unique mechanism of how ERa dimerization is negatively controlled by interaction with 14-3-3 proteins at the extreme C terminus of the receptor. Moreover, the small-molecule fusicoccin (FC) stabilizes this ERa/14-3-3 interaction. Cocrystallization of the trimeric ERa/14-3-3/FC complex provides the structural basis for this stabilization and shows the importance of phosphorylation of the penultimate Threonine (ERa-T594) for high-affinity interaction. We confirm that T594 is a distinct ERa phosphorylation site in the breast cancer cell line MCF-7 using a phospho-T594–specific antibody and by mass spectrometry. In line with its ERa/14-3-3 interaction stabilizing effect, fusicoccin reduces the estradiol-stimulated ERa dimerization, inhibits ERa/chromatin interactions and downstream gene expression, resulting in decreased cell proliferation. Herewith, a unique functional phosphosite and an alternative regulation mechanism of ERa are provided, together with a small molecule that selectively targets this ERa/14-3-3 interface.

AB - Estrogen receptor alpha (ERa) is involved in numerous physiological and pathological processes, including breast cancer. Breast cancer therapy is therefore currently directed at inhibiting the transcriptional potency of ERa, either by blocking estrogen production through aromatase inhibitors or antiestrogens that compete for hormone binding. Due to resistance, new treatment modalities are needed and as ERa dimerization is essential for its activity, interference with receptor dimerization offers a new opportunity to exploit in drug design. Here we describe a unique mechanism of how ERa dimerization is negatively controlled by interaction with 14-3-3 proteins at the extreme C terminus of the receptor. Moreover, the small-molecule fusicoccin (FC) stabilizes this ERa/14-3-3 interaction. Cocrystallization of the trimeric ERa/14-3-3/FC complex provides the structural basis for this stabilization and shows the importance of phosphorylation of the penultimate Threonine (ERa-T594) for high-affinity interaction. We confirm that T594 is a distinct ERa phosphorylation site in the breast cancer cell line MCF-7 using a phospho-T594–specific antibody and by mass spectrometry. In line with its ERa/14-3-3 interaction stabilizing effect, fusicoccin reduces the estradiol-stimulated ERa dimerization, inhibits ERa/chromatin interactions and downstream gene expression, resulting in decreased cell proliferation. Herewith, a unique functional phosphosite and an alternative regulation mechanism of ERa are provided, together with a small molecule that selectively targets this ERa/14-3-3 interface.

U2 - 10.1073/pnas.1220809110

DO - 10.1073/pnas.1220809110

M3 - Article

C2 - 23676274

VL - 110

SP - 8894

EP - 8899

JO - Proceedings of the National Academy of Sciences of the United States of America (PNAS)

JF - Proceedings of the National Academy of Sciences of the United States of America (PNAS)

SN - 0027-8424

IS - 22

ER -